Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs: A Retrospective, Population-Based Study of Medicaid Claims Data
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Increased risk of diabetes and dyslipidemia is associated with major mental illness and antipsychotic drug use. This study aimed to determine the prevalence of serum glucose and lipid monitoring in public mental health clients initiating second-generation antipsychotic (SGA) drugs. METHOD: This retrospective cohort study using Medicaid claims data from California, Oregon, Tennessee, and Utah evaluated 55,436 enrollees with a prescription claim for an SGA drug between January 1, 1998, and December 31, 2003. Serum glucose and lipid testing were identified using Current Procedural Terminology (CPT) procedure codes. Baseline was defined as 14 days before through 28 days after the date of the first SGA prescription. Multivariate logistic regression identified patient characteristics associated with testing. Generalized estimating equations evaluated changes associated with SGA drug initiation compared to background rates of testing. RESULTS: On average, < 20% of individuals initiating SGA drug therapy received baseline glucose testing, and < 10% received baseline lipid testing. Baseline glucose and lipid testing increased modestly with SGA initiation (glucose: 7%-11% increase; lipids: 2%-3% increase; p < .001). Preexisting diabetes and dyslipidemia were associated with a 2- to 3-fold greater likelihood of baseline glucose and lipid testing. The likelihood of glucose testing increased 2-fold between 1998 and 2003 and was 46% more likely in patients with schizophrenia. Enrollees from Oregon, Tennessee, and Utah were 50% to 90% less likely to receive baseline glucose or lipid testing than enrollees from California. CONCLUSIONS: Glucose and lipid screening is underutilized in patients initiating SGA drug therapy. Psychiatrists can play an important role to ensure metabolic risk is adequately assessed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality and causes of death in schizophrenia in Stockholm County, Sweden
Ösby, U., Correia, N., Brandt, L., Ekbom, A., & Sparén, P. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00191-7 · Cited by 679
Disparities in Diabetes Care: Impact of Mental Illness
Frayne, S. M., Halanych, J. H., Miller, D. R., Wang, F., Lin, H., Pogach, L., Sharkansky, E. J., Keane, T. M., Skinner, K. M., Rosen, C. S., et al. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.22.2631 · Cited by 336
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
“Evidence suggests that people with schizophrenia are not being adequately screened and treated for dyslipidemia (up to 88% untreated) and hypertension (up to 62% untreated) (35,306,340-343).”
BackgroundSelf-citationCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050
Severe Mental Illness and Risk of Cardiovascular Disease
Newcomer, J. W., & Hennekens, C. H. (2007) · JAMA · doi:10.1001/jama.298.15.1794 · Cited by 433
Self-citationDe Hert, M., Dobbelaere, M., Sheridan, E. M., Cohen, D., & Correll, C. U. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2010.09.011 · Cited by 362
Mitchell, A. J., Delaffon, V., Vancampfort, D., Correll, C. U., & De Hert, M. (2012) · Psychological Medicine · doi:10.1017/s003329171100105x · Cited by 332
“…et al. 2007 ; Mackin et al. 2007 ; Natarajan & D’Silva, 2007 ; Voruganti et al. 2007 ; Barnes et al. 2008 ; Hsu et al. 2008; Jennex & Gardner, 2008 ; Morrato et al. 2008, 2009a, b, 2010 ; Crabb et al. 2009 ; Haupt et al. 2009; Holt et al. 2009 ; Nguyen et al. 2009 ; Shi et al. 2009 ; Batscha et…”
Influential
Metadata
- Authors
- Morrato, E. H., Newcomer, J. W., Allen, R. R., & Valuck, R. J.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-02-15
- Volume
- 69
- Issue
- 2
- Pages
- 316-322
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2088209318
- Cited by
- 104
- References
- 2
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs: A Retrospective, Population-Based Study of Medicaid Claims Data. https://app.cochat.ai/papers/10.4088/jcp.v69n0219
- The paper
- Morrato, E. H., Newcomer, J. W., Allen, R. R., & Valuck, R. J. (2008). Prevalence of Baseline Serum Glucose and Lipid Testing in Users of Second-Generation Antipsychotic Drugs: A Retrospective, Population-Based Study of Medicaid Claims Data. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v69n0219
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.